Abstract
Late-onset (≥50 years) relapsing remitting Multiple Sclerosis (LORRMS) is associated with adverse prognosis but established marker(s) of such poor prognosis are still lacking in the clinical practice. The aim of the study is to compare effectiveness of injectable and oral first line disease modifying therapies (DMTs) in a cohort of patients with LORRMS for time to first relapse, time to confirmed disability progression (CDP), and, additionally, for time to discontinuation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have